ERBB3 and neoplasm: Further supporting a precision medicine approach, recent studies using both patient-derived organoids and mouse models demonstrated that combining an anti-HER3 antibody with a topoisomerase I inhibitor in the form of an antibody–drug conjugate (ADC) effectively halted tumor proliferation in HER3-high prostate cancers [23].